United-Guardian, Inc. — 2011 Form 10-K
Business context and reporting period
Reports the fiscal year ended December 31, 2011, compared with 2010. This is an annual filing; standalone fourth-quarter results are not clearly provided. The company manufactures and markets personal-care and cosmetic ingredients, pharmaceuticals, medical products, and specialty industrial products. LUBRAJEL and RENACIDIN together accounted for about 94% of 2011 revenue; the company operates in one business segment.
Financial performance and position
| Metric | 2011 | 2010 |
|---|---|---|
| Net sales | $14.34 million | $13.72 million |
| Gross profit | $8.69 million; 60.6% margin | $8.47 million; 61.7% margin |
| Operating income | $6.14 million | $5.06 million |
| Net income | $4.72 million | $3.80 million |
| Basic and diluted EPS | $1.03 | $0.80 |
| Cash from operations | $4.44 million | $4.09 million |
- Sales rose 4.5%, while net income rose 24.1%. Calculated net margin was approximately 32.9%, versus 27.7% in 2010. The 2010 comparison includes an $847,744 pension-plan termination charge; without that unusual charge, the reported increase in operating income is less representative of underlying growth.
- Cost of sales increased to 39.4% of sales from 38.3%, reflecting higher raw-material and direct-labor costs.
- At year-end, cash and cash equivalents were $1.09 million and marketable securities were $9.30 million. Working capital was $12.90 million and the current ratio was 13.0:1. No debt is shown on the balance sheet; management reported no credit line and no foreseeable need for one.
- Investing activities used $1.18 million; financing activities used $3.68 million, entirely reported as dividends paid. Cash declined by $424,000 during the year.
- The company paid semi-annual dividends of $0.36 and $0.44 per share in 2011, totaling $0.80 per share.
Material changes versus 2010
- Personal-care sales increased $846,000, or 10.1%, primarily through higher sales to major marketing partner ASI. LUBRAJEL sales across personal-care and medical uses increased 9.8%; volume increased about 8.7%.
- Pharmaceutical sales declined $401,000, or 14.8%, principally because RENACIDIN production was interrupted. RENACIDIN represented about 13% of sales, versus 17% in 2010.
- Non-pharmaceutical medical sales increased 10.9%; industrial and other sales declined 20.9%.
- Operating expenses decreased 0.6%. Research and development expense increased to about $637,000 from $596,000.
Outlook, risks, contingencies, and unusual items
- Management expected 2012 R&D expense to be comparable to 2011 and believed working capital sufficient for the next fiscal year. It hoped RENACIDIN sales would recover toward historical levels after regular production resumed in May 2011; year-end monthly sales remained below historical levels.
- Management expected KLENSOFT sales in 2012 to be similar to 2011. It expected at least one LUBRAJEL NATURAL formulation to be ready for marketing in 2012 and anticipated LUBRAJEL TF sales could begin in 2012. These are expectations, not assurances.
- The RENACIDIN supplier interruption led to a $385,182 damage-settlement payment recognized as other income in 2011; approximately $4,800 remained expected in 2012. Management attributed about $390,000 of lost gross profit to the disruption.
- Sales and receivables are concentrated: two distributor/marketing-partner customers generated about 58% of 2011 revenue, and one represented about 47% of year-end receivables. Foreign sales were approximately 59.5% of revenue. Five vendors supplied about 83% of raw-material purchases.
- Key risks include reliance on marketing partners, customer and supplier concentration, competition, raw-material price and availability, economic conditions, regulatory requirements, and acceptance of products under development. The company noted UNITWIX raw-material cost and availability concerns and possible discontinuation of CONFETTI if sales do not improve.
- The company reported no legal proceedings, material off-balance-sheet arrangements, or material environmental-law impact. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not attest to internal-control effectiveness.
Important facts for investors to verify
- Whether RENACIDIN production and sales recovered as management anticipated, and whether the supplier paid the remaining settlement amount.
- Whether growth and customer retention at ASI and other distributors continued, given the high revenue and receivables concentration.
- Whether higher raw-material and labor costs affected margins, and whether UNITWIX II secured customer adoption and reliable raw-material supply.
- Whether 2012 product-development plans—including LUBRAJEL NATURAL and LUBRAJEL TF—advanced to commercial sales.
- The composition, liquidity, and valuation risk of the $9.30 million marketable-securities portfolio, including management’s conclusion that unrealized declines were temporary.